Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $3.80

Century Therapeutics, Inc. (NASDAQ:IPSC) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $3.80.

IPSC has been the subject of a number of research reports. Leerink Partners cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Piper Sandler lifted their price target on Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Zacks Research upgraded Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Finally, Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 1st.

Century Therapeutics Stock Performance

Century Therapeutics stock opened at $1.79 on Thursday. The stock has a market cap of $156.45 million, a P/E ratio of -5.59 and a beta of 1.75. Century Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.71. The firm’s fifty day moving average price is $1.44 and its 200-day moving average price is $0.85.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Sell-side analysts predict that Century Therapeutics will post -1.61 earnings per share for the current year.

Insider Activity

In related news, insider Chad Cowan bought 58,060 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average cost of $0.85 per share, for a total transaction of $49,351.00. Following the acquisition, the insider directly owned 1,045,087 shares of the company’s stock, valued at $888,323.95. The trade was a 5.88% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brent Pfeiffenberger purchased 52,000 shares of Century Therapeutics stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer owned 3,322,990 shares in the company, valued at $1,927,334.20. The trade was a 1.59% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 145,060 shares of company stock valued at $97,011 and have sold 66,018 shares valued at $30,213. Corporate insiders own 4.37% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP boosted its position in Century Therapeutics by 59.2% during the 3rd quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after buying an additional 338,902 shares during the period. GSA Capital Partners LLP increased its stake in shares of Century Therapeutics by 29.3% during the third quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock valued at $301,000 after buying an additional 136,873 shares during the period. Geode Capital Management LLC raised its holdings in shares of Century Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock valued at $454,000 after acquiring an additional 10,806 shares in the last quarter. Jane Street Group LLC bought a new stake in Century Therapeutics in the second quarter valued at $248,000. Finally, Citadel Advisors LLC increased its position in Century Therapeutics by 64.1% during the 3rd quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after purchasing an additional 140,891 shares during the period. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.